To accurately screen out patients who can benefit from the different treatment regimens, we classified patients into responders (Rs) and non‐responders (NRs) and analyzed TIME features, including PD‐L1 expression and densities of different T cell and tumor‐associated macrophage (TAM) subsets, two major immunocyte components in the TME [16]. This evidence concerns the gene CD274 and neoplasm.